#Japan #Bridgewater #Insmed #Bronchiectasis #Brinsupri

Insmed Unveils BRINSUPRI® Tablets for Non-Cystic Fibrosis Bronchiectasis in Japan

Insmed Incorporated, a global biopharmaceutical powerhouse focused on patient-centric therapies, recently marked a significant milestone with the launch of BRINSUPRI® Tablets 25 mg (brensocatib hydrate). This pioneering oral medication has been specially designed for the treatment of non-cystic fibrosis bronchiectasis (NCFB) and is now available by prescription across Japan for adults and pediatric patients aged 12 and above.

The release of BRINSUPRI in Japan is set to transform the lives of countless patients suffering from this chronic lung disease. According to Samuele Butera, Insmed's Senior Vice President and General Manager of Global Respiratory, the commercial availability of this therapy represents a substantial turning point for the bronchiectasis community. He expressed pride in the team's efforts to provide a treatment that addresses the unresolved issues related to the underlying inflammatory processes of NCFB.

What Sets BRINSUPRI Apart?
BRINSUPRI is not just another treatment; it is the first and only approved therapy specifically targeting NCFB in Japan. The Japanese Ministry of Health, Labour, and Welfare (MHLW) granted approval in August 2026, following positive results from the pivotal Phase 3 ASPEN study. During this trial, evidence emerged indicating that BRINSUPRI significantly mitigates recurrent exacerbations, which have long posed a burden on patients suffering from bronchiectasis.

Understanding Bronchiectasis
Bronchiectasis is characterized by the permanent dilation of the bronchi, caused by a vicious cycle of infections and inflammation leading to lung tissue damage. Symptoms include chronic coughing, excessive sputum production, shortness of breath, and frequent respiratory infections—conditions that severely impede the quality of life.

Importantly, most adult cases of bronchiectasis fall under the category of non-cystic fibrosis bronchiectasis (NCFB), underscoring the urgency for targeted treatment options like BRINSUPRI. Makoto Nakamura, Senior Vice President and General Manager for Insmed Japan, highlighted the potential for BRINSUPRI to improve the management of this disease and alleviate the challenges faced by healthcare providers in treating eligible patients.

How BRINSUPRI Works
BRINSUPRI (brensocatib) operates as a small molecule, taken once daily, that acts as a reversible inhibitor of dipeptidyl peptidase 1 (DPP1). This mechanism effectively curtails the activation of specific enzymes linked to chronic airway inflammation, significantly impacting the condition of patients suffering from NCFB.

Globally, BRINSUPRI is approved in the United States and the European Union, expanding its reach and enhancing the treatment landscape for chronic lung diseases. In Japan, BRINSUPRI is indicated for patients aged 12 and older who experience two or more exacerbations within a span of 12 months.

Commitment to Patient Care
Insmed continues to uphold its commitment to the bronchiectasis community by ensuring that healthcare professionals receive necessary resources and information for the effective deployment of this therapy. With ongoing support, Insmed aims to make BRINSUPRI a vital part of the treatment regimen for those affected by NCFB, thereby enhancing their everyday lives.

Overall, the introduction of BRINSUPRI® Tablets in Japan heralds a new chapter in the fight against bronchiectasis, promising hope and much-needed assistance to patients who have long been in search of effective medical solutions. This launch not only signifies advancement in medical therapy but also reflects Insmed’s dedication to addressing unmet medical needs and improving patient outcomes across the globe.